Zedira supports 2nd International Factor XIII Workshop
September 22nd, 2016
Zedira is very proud to support for the 2nd International Factor XIII Workshop dedicated to coagulation factor XIII. The workshop will be held from September 28 - October 2, 2016, in Hévíz, Hungary.
Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.
News
Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
Press release: Additional subsidy funding for clinical development of a celiac disease drug
Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation
Blog
Microbial transglutaminase: from discovery to market
Tissue transglutaminase inhibitors
Tissue transglutaminase in Alzheimer’s Disease
Factor XIIIa: novel target for anticoagulation?
Microbial transglutaminase for site-specific protein conjugation
Transglutaminase antibodies in ataxia
Events
Life Sciences 2019: Post-translational modifications and cell signalling
17.03.2019 - 18.03.2019
Nottingham, UK
10th International meeting of the Society for research on the Cerebellum and Ataxias (SRCA)
Microbial transglutaminase: from discovery to market
Tissue transglutaminase inhibitors
Tissue transglutaminase in Alzheimer’s Disease
Factor XIIIa: novel target for anticoagulation?
Microbial transglutaminase for site-specific protein conjugation
Transglutaminase antibodies in ataxia